ℹ️ Compiled from public regulatory records · Last regulator revision: May 22, 2026🚩 Report this page
Molnupiravir
Nucleosides and Nucleotides Excl. Reverse Transcriptase Inhibitors
Sold as LAGEVRIO
GB MHRA
- Drug class
- Nucleosides and Nucleotides Excl. Reverse Transcriptase Inhibitors
- Availability
- See label
- Markets covered
- 1
- Products on record
- 2
Overview
Molnupiravir is an active pharmaceutical ingredient in the Nucleosides and Nucleotides Excl. Reverse Transcriptase Inhibitors group (J05AB). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 2 | May 22, 2026 |
GBUnited Kingdom· MHRA
2 products
Uses
1 for information on posology and limits of clinical trial population).
How to take
Sources & citations
- [1]MHRA (UK) · PLGB530950099 · revised May 22, 2026
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.